UBX Logo

Unity Biotechnology, Inc. (UBX) 

NASDAQ
Market Cap
$19.04M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
397 of 776
Rank in Industry
207 of 433

Largest Insider Buys in Sector

UBX Stock Price History Chart

UBX Stock Performance

About Unity Biotechnology, Inc.

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye …

Insider Activity of Unity Biotechnology, Inc.

Over the last 12 months, insiders at Unity Biotechnology, Inc. have bought $0 and sold $8,680 worth of Unity Biotechnology, Inc. stock.

On average, over the past 5 years, insiders at Unity Biotechnology, Inc. have bought $56,956 and sold $2.25M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 6,400 shares for transaction amount of $56,956 was made by David Nathaniel E (President) on 2020‑06‑05.

List of Insider Buy and Sell Transactions, Unity Biotechnology, Inc.

2024-11-04SaleChief Executive Officer
432
0.0026%
$1.29$557-12.40%
2024-11-04SaleCFO & Head of Corp. Dev.
136
0.0008%
$1.29$175-12.40%
2024-11-04SaleChief Legal Officer
149
0.0009%
$1.29$192-12.40%
2024-08-02SaleChief Executive Officer
604
0.0038%
$1.53$924-1.03%
2024-08-02SaleCFO & Head of Corp. Dev.
139
0.0009%
$1.53$213-1.03%
2024-08-02SaleChief Legal Officer
154
0.001%
$1.53$236-1.03%
2024-06-25SaleChief Executive Officer
1,214
0.0072%
$1.40$1,700+2.84%
2024-06-25SaleCFO & Head of Corp. Dev.
324
0.0019%
$1.40$454+2.84%
2024-06-25SaleChief Legal Officer
78
0.0005%
$1.40$109+2.84%
2024-05-02SaleChief Executive Officer
603
0.0034%
$1.55$935-9.82%
2024-02-02SaleChief Executive Officer
680
0.0041%
$1.71$1,163-14.20%
2024-01-30SaleChief Executive Officer
1,183
0.0072%
$1.71$2,023-10.59%
2023-11-02SaleChief Executive Officer
589
0.0037%
$1.83$1,078-20.71%
2023-10-30SaleChief Executive Officer
1,024
0.0069%
$1.90$1,946-17.71%
2023-09-14SaleChief Executive Officer
1,246
0.0085%
$2.47$3,078-32.79%
2023-08-02SaleChief Executive Officer
581
0.0043%
$2.94$1,708-36.84%
2023-07-31SaleChief Executive Officer
1,020
0.0075%
$2.86$2,917-36.82%
2023-06-26SaleChief Executive Officer
1,177
0.0085%
$3.20$3,766-41.48%
2023-06-14SaleChief Executive Officer
1,212
0.0087%
$3.39$4,109-44.71%
2023-05-02SaleChief Executive Officer
588
0.004%
$2.17$1,276-13.06%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Arch Venture Management Llc$1.65M5.991M0%+$00.08
Alyeska Investment Group L P$1.51M5.48920,013-11.65%-$198,961.480.01
The Vanguard Group$914,059.003.32557,353-0.76%-$6,968.36<0.0001
Geode Capital Management$220,035.000.8134,133+1.78%+$3,856.64<0.0001
Mayo Clinic$203,493.000.74124,0810%+$00.02
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.